Unicycive Therapeutics (UNCY)
(Delayed Data from NSDQ)
$0.46 USD
+0.02 (3.86%)
Updated Jul 26, 2024 04:00 PM ET
After-Market: $0.46 0.00 (0.66%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth F Momentum F VGM
Price, Consensus and EPS Surprise
UNCY 0.46 +0.02(3.86%)
Will UNCY be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for UNCY based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for UNCY
Unicycive (UNCY) Up on Positive Hyperphosphatemia Study Update
UNCY: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for UNCY
Unicycive Therapeutics management to meet virtually with Piper Sandler
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
Unicycive Therapeutics Granted Patent on UNI-494 to Treat Acute Kidney Injury by the United States Patent and Trademark Office (USPTO)
Unicycive Therapeutics granted patent on UNI-494 from USPTO
Unicycive Therapeutics to Participate in Fireside Chat at the H.C. Wainwright 3rd Annual Kidney Virtual Conference